The application effect of Opicapone in the treatment of Parkinson's disease

Opicapone is a new type of peripheral COMT (catechol-O-methyltransferase) inhibitor. As an auxiliary treatment drug for Parkinson's disease, it is mainly used in combination with levodopa (Levodopa) to treat the "end-of-dose fluctuation" phenomenon in patients with moderate to advanced Parkinson's disease. As Parkinson's disease progresses, patients' response to levodopa gradually becomes unstable, often manifesting as a shortened duration of drug effect and waxing and waning symptoms. This phenomenon is medically known as "interspersed fluctuations" or "switching phenomena." Opicapone blocks the degradation of levodopa by peripheral COMT enzymes, allowing more levodopa to enter the central nervous system, thus prolonging the maintenance time of drug efficacy, reducing fluctuations, and improving the quality of daily life.

Among the existing treatment options, the biggest advantage of Opicapone is its long-acting effect. Compared with the traditional COMT inhibitor Entacapone, Opicapone has a longer duration of action and only needs to be administered once a day to maintain its 24-hour effect. This feature not only improves patient compliance, but also significantly reduces the complexity of dose management caused by high frequency of medication. According to the recommendations of European and American Parkinson's disease treatment guidelines, Opicapone is suitable for patients with obvious fluctuations in response to levodopa treatment, especially for mid-to-late-stage patients who need to stabilize the drug effect and reduce the "off period" time.

In clinical practice, the combination of opicapone and levodopa can prolong the "on period" time, reduce the frequency and intensity of the "off period", and have a positive effect on improving daytime activity ability. Not only were motor symptoms effectively relieved, some patients also reported improved mood and reduced fatigue, which may be related to the improvement in overall neurological function brought about by stable levodopa concentrations.

Since Opicapone mainly acts in the periphery and does not penetrate the blood-brain barrier, it is relatively superior in terms of safety and has less side effects on the central nervous system.

Reference materials:https://www.ongentys.com/